We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Image of Katie Brighton

Katie Brighton

Scientific Copywriter

Contact Us

Katie joined Technology Networks in January 2022 after completing a bachelor’s degree in biochemistry and a master’s by research degree in molecular and cellular biology, both at the University of Leeds. They loved the breadth of scientific content covered in their undergraduate studies and wanted to share their passion for research through science communication. As a scientific copywriter, Katie assembles newsletters, writes promotional webinar copy, supports the publication’s in-house writers and produces scientific content.

Latest Content
Industry Insight

Extending the Reach of Psychedelic Therapy With Psychoplastogens

Delix Therapeutics is developing non-hallucinogenic psychedelics for use as at-home medications for mental health conditions. To find out more, we spoke to the CEO, Mark Rus.
Industry Insight

The Impact of Funding on Longevity Research

To find out more about how early-stage funding could improve longevity research, we had the pleasure of speaking to Garri Zmudze, executive director of the Longevity Science Foundation.

Re-Educating the Immune Response To Treat Type 1 Diabetes

CAR T-cell therapy is largely used to treat cancers, but here we explore how Dr. Leonardo Ferreira and his team are using CAR T-cell therapy to treat Type 1 diabetes.
Industry Insight

Treating C. diff Infection and More With Gut Microbiome Transplants

Technology Networks had the pleasure of speaking to Thomas Lendvay, CMO and co-founder of Tend about the current applications of gut microbiota transplants and how they could be used in future.

Opinionated Science Episode 42: Caffeine for ADHD and Cancer-Sniffing Worms

In this episode of Opinionated Science, the team discusses a new advance that uses a microscopic worm to sniff out lung cancer, why caffeine is being investigated to treat ADHD and a stats study that may undermine an important area of neuroscience.

Industry Insight

Identifying Risk Factors for Long COVID With Single-Cell Proteomics

In this interview we speak to Sean Mackay, CEO of IsoPlexis, to discuss how single-cell functional proteomics have helped researchers understand the risk factors behind long COVID.
Industry Insight

Developing Chicken-Free Egg Whites

Cellular agriculture could provide a more sustainable way to meet the demand for eggs. We spoke to Maija Itkonen, CEO of Onego Bio, to find out more about their chicken-free egg white.
Industry Insight

Driving Progress in Personalized Cancer Therapy

Personalized medicine has the potential to change the cancer patient's journey by predicting how they will respond to different treatments. Technology Networks spoke to Dr. Ofer Sharon, CEO of OncoHost, to find out more!
Industry Insight

Exploiting Bacteriophage as a Diagnostic Tool

Technology Networks spoke to Dr. Tomas Richardson from PBD Biotech, to hear more about how bacteriophage can be used to diagnose tuberculosis in both humans and cattle.
Industry Insight

The Genome in 3D – How Chromatin Conformation Impacts Gene Regulation

Three-dimensional interactions across the genome can impact gene expression, and understanding these interactions could offer new insights into oncogenic mechanisms.